Cost Effectiveness analyses

Recommended reading :

Statistical Analysis of Cost-Effectiveness Data (Statistics in Practice) (Hardcover) by Andrew R. Willan (Author), Andrew H. Briggs (Author) "There is a growing expectation from health care policymakers that evidence supporting the cost-effectiveness of new health care interventions, particularly pharmaceuticals, be provided along with..." (more)

Lamers LM, Stupp R, van den Bent MJ, Al MJ, Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R, Uyl-de Groot CA; Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme : a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer. 2008 Jan 22 [Epub ahead of print]

Tjan-Heijnen VC, Caleo S, Postmus PE, Ardizzoni A, Burghouts JT, Buccholz E, Biesma B, Gorlia T, Crott R, Giaccone G, Debruyne C, Manegold C; European Organisation for Research Treatment of Cancer-Lung Cancer Group and Health Economics Unit ; Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923); Ann Oncol. 2003 Feb;14(2):248-57.

Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccart M ; Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. Pharmacoeconomics. 2002;20(7):485-97. Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M.; Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ. 2002 Apr;11(3):233-48. Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M, Brochon D. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis. Eur J Cancer. 2001 Sep;37(14):1768-74.